Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | CCR2 | P41597 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849609 | 0.87 | CNR2 (0.40) | TP53MAPTCNR2CCR2POLB | |
| SCHEMBL5849849 | 0.86 | TP53 (0.41) | TP53MAPTCNR2CCR2POLB | |
| SCHEMBL5851464 | 0.82 | HDAC6 (0.43) | TP53MAPTCNR2CCR2MME | |
| SCHEMBL5849421 | 0.81 | NPC1 (0.40) | TP53MAPTCNR2CCR2POLB | |
| SCHEMBL5849296 | 0.79 | CNR2 (0.60) | MAPTCNR2 | |
| SCHEMBL5849331 | 0.79 | CNR2 (0.42) | TP53MAPTCNR2CCR2MME | |
| SCHEMBL2214890 | 0.72 | CNR2 (0.46) | CNR2POLBCYP19A1 | |
| SCHEMBL2215683 | 0.72 | CYP19A1 (0.57) | MAPTCNR2CCR2CYP19A1 | |
| SCHEMBL5849422 | 0.71 | MEN1 (0.48) | TP53CNR2TSPO | |
| SCHEMBL27899802 | 0.70 | MAPT (0.54) | TP53MAPTCCR2POLBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | claimed |
| US-7138408-B2 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | POLB, POLA1, TYMP | TP53 2299/4885MAPT 2600/4885CNR2 3950/4885 |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | POLB, APOBEC3C, IDH3A | TP53 2178/4885MAPT 2416/4885CNR2 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.